Precision Medicine Initiative (PMI) Committee Meeting

April 17, 2024

NIH NATIONAL CANCER INSTITUTE

Agenda

- Roll Call
- Project Updates
- Action Items
- MM Paper STMF Updates
- RAVE Forms Review
- Open Discussion

Stakeholder Representation



Project Updates

Project Updates – PMI Deliverables

	Deliverable	Target Release Date	Target Release Vehicle
☑	**ComboMATCH changes** (Disease fields, histology, behavior field code)	**PROD Released: July 17, 2023**	**Screening Protocol EC Template v2.0**
☑	**Designated Labs for Combo**	**PROD Released: Sept 6, 2023**	**Screening Protocol EC Template v3.0** *(UAT Release w/EA – 07/27/2023)*
☑	**Re-Screening ComboMATCH**	**PROD Released: Sept 27, 2023**	**MSRP Re-Screening EC Template v1.0** *(UAT Release w/EA – 07/27/2023)*
☑	**Cohort Migration**	**PROD OPEN Released: Sept 28, 2023** **PROD EC Temp v1.0 Released: *Oct 27, 2023***	**Treatment Protocol Cohort Migration EC Template v1.0**
☑	**MyeloMATCH Tx Protocol Crossover** (for S01, CTG01 and EA02)	*n/a*	Part of the existing Treatment Protocol workflow; no PRODUCTION OPEN Release required; the Westat team is prepared to support this workflow as Groups begin using it.
☑	**Re-Screening MM**	**PROD RS EC Temp v2.0 Released: *Nov 30, 2023***	No PRODUCTION OPEN Release is required for MM Re-Screening activities; the Westat team is prepared to support this workflow as Groups begin using it. **MSRP Re-Screening EC Template v2.0** *(UAT Release w/SWOG – 10/6/2023; 2nd UAT Release w/SWOG – 10/24/2023; 3rd UAT Release to SWOG – 11/07/2023; PROD RS EC Template v2.0 target date 11/30/2023)*
☐	**MyeloMATCH Stratification**	*PROD OPEN Release: February 12, 2023*	Part of existing Treatment Protocol Workflow.
☑	**BETA PMI Screening Protocol ALS v2.0** *New Forms: STMF, CLIA, PATH GROUP*	**Released:** *BETA Release: January 12, 2024*	Target date for BETA Release for Groups to initiate UAT activities. *(accompanied by BETA Screening Protocol Central Study ALS v2.0)*
☐	**PROD PMI Screening Protocol ALS v2.0** *New Forms: STMF, CLIA, PATH GROUP*	*PROD Release: April 22, 2024*	Target date for PRODUCTION Release for Groups to initiate implementation activities. *(accompanied by PROD Screening Protocol Central Study ALS v2.0)*

Project Updates - EC Template Release Schedule

Template	Version	UAT Release Date	PROD Release Date	Details
PMI Screening Protocol EC Template	V1.0	Released: 12/16/2022	**Released: 02/15/2023**	
PMI Screening Protocol EC Template	V2.0	Released: 05/01/2023	**Released: 07/17/2023**	Includes CM changes (Disease fields, histology, behavior field code)
PMI Screening Protocol EC Template	V3.0	Released: 07/27/2023	**Released: 09/06/2023**	Includes updates for Designated Labs (DLAP fields)
PMI Screening Protocol EC Template Fact Sheet	*v3.1*	*n/a*	*Released: 10/6/2023*	Administrative version/release of the Fact Sheet to capture MyeloMATCH Field Help/Instructional Text for the 'Prior therapy name' field; to be used in conjunction with the PMI Screening Protocol EC Template v3.0.
PMI Treatment Protocol EC Template	V1.0	Released: 12/16/2022	**Released: 02/15/2023**	
PMI Treatment Protocol EC Template Fact Sheet	*V1.1*	*n/a*	**Released:** *11/16/2023*	Administrative version/release of the Fact Sheet to provide a stand-alone TX Protocol-specific document allows Groups to easily access the Fact Sheet information; to be used in conjunction with the PMI Treatment Protocol EC Template v1.0.
PMI MSRP Re-Screening EC Template	V1.0	Released: 07/27/2023	**Released: 09/27/2023**	*Supports ComboMATCH MSRP.*
PMI MSRP Re-Screening EC Template	V2.0	Re-released: 11/07/2023 Re-released: 10/24/2023 Released: 10/06/2023	**Released***:* **11/30/2023**	*Supports MyeloMATCH MSRP; PROD release date confirmed.*
PMI Treatment Protocol Cohort Migration EC Template	V1.0	Released: 09/18/2023	**Released: 10/27/2023**	Supports cohort migration activities for ComboMATCH.
PMI Treatment Protocol Cohort Migration EC Template Fact Sheet	*v1.1*	Re-Release*: 10/4/2023*	**Released***: 10/27/2023*	Administrative version/re-release of the UAT Fact Sheet to capture updated Field Help/Instructional Text for the 'Cohort migration assignment' field; to be used in conjunction with the UAT PMI Treatment Protocol Cohort Migration EC Template v1.0.

ComboMATCH Priority 1 List

#	Protocol #	Protocol Title	Group	Activated	Current Status
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	Yes	3/20: No updates 4/3: No updates 4/17: No updates
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	Yes	2/21: No Updates 3/20: No updates 4/3: No updates 4/17: : No updates
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	Yes	2/21: No Updates 3/20: No updates 4/3: Temp suspended 4/17: Temp suspended
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	Yes	2/21: Protocol Submitted – working on updates 3/20: No updates 4/3: Amendment approved…releasing April 15th. 4/17: Amendment released on 4/15
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	Yes	2/21: No updates 3/20: No Updates 4/3: No updates 4/17: No updates

ComboMATCH Priority 2 List

#	Protocol #	Protocol Title	Group	Activated	Current Status
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Yes	2/21: No Updates 3/20: No Updates 4/3: Going through getting IDs into OPEN to work on ECs 4/17: No Updates
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Yes	2/21: No Updates 3/20: Suspend Cohort 3. 4/3: No updates, : Suspend Cohort 3. 4/17: Working on protocol update

ComboMATCH Priority 3 List

#	Protocol #	Protocol Title	Group	Current Status
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	**DROPPED**
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	**DROPPED**
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	**2/21: No Updates** **3/20: No updates** **4/3: No updates** **4/17: No Updates**
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	**1/10: No Updates** **2/7: Released to production on 2/12** **2/21: No updates** **3/20: No updates** **4/3: No updates** **4/17: No Updates**

MyeloMATCH Priority 1 List

#	Protocol #	Protocol Title	Group	Current Status
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	**3/20: Pending FFP; having trouble getting a volunteer for testing. If we do not identify someone soon, we will need to use an internal person.** **4/3: Going through FFP; almost completed** **4/17: Testing is complete; ready for activation**
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	**3/20: Halfway through integration testing, have a few bugs they are working through.** **4/3: Going through FFP; almost completed; sent email template messages out for feedback** **4/17: Testing is complete for FFP; still completing internal UAT for a few weeks to prepare for activation**
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	**3/20: Working on integration testing, received extra test patients. Put in a request with CTSU for a fix. Identified sites for FFP testing.** **4/3: Integration testing and FFP testing; issues with Withdrawal consent and treatment but working with Westat** **4/17: Finishing up FFP Testing; won't need additional testing unless something comes up in FFP**
6	MM1OA-EA02	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	**3/20: Working on integration testing, hoping to complete in the next few days. Reached out to FFP testing, waiting on the sites to get back to us.** **4/3: FFP testing is completed; finalizing Rave build, working on validation** **Action Item: Leila will reach out for feedback** **4/17: Ready for activation; finalizing build for OPEN**

MyeloMATCH Priority 2 List

#	Protocol #	Protocol Title	Group	Current Status
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to Stem Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	**2/21: No Updates** **3/20: No Updates** **4/3: No updates** **4/17: No Updates**
5	MM1OA-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	**2/21: No Updates** **3/20: No Updates** **4/3: Begin this soon as FFP is almost done; build has started; will take about a month until integration testing** **4/17: Waiting to complete internal UAT for SO1 to move forward**
7	MM1MDS-EA03 (Concept	ERADICATE MDS with TP53 Study: Efficacy of targeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for Treatment of Higher Risk Myelodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	**2/21: Withdrawn**

PMI Committee Call Action items

Action Items from 4.3.24 Meeting

Action Items (from 4/3/24)	Details
Reassignment Workflow- Group to review and confirm if “slot expired’ option would require additional protocol amendments	Per SWOG Team: For MyleoMATCH, the protocol wording is loose enough that it doesn’t need to be updated to accommodate this option, but SWOG team will double check to make sure. • Keeping the same 10-day window for the second slot would be fine. *Integrations team will review the impacts of this addition and present for decision on moving forward, including identifying the timeline for the updates*
Reassignment Workflow- Integrations team to confirm where the ‘request reassignment process’ would be documented	Determined that Reassignment workflow details will be included in the CM Primer document that is to be released. The document is yet to be updated and released. After additional work on the document is completed, a release date will be shared.

MM Paper STMF Updates

Updated MM Paper STMF Form

- Form updated to make it easier and more effective for Site users
  - Field and value edits
  - PDF-fillable format & radio buttons
  - Improved formatting and placement of text
  - Condensed verbiage where applicable
- Example form will be
  - Sent out to all groups via email for awareness
  - Posted to the PMI Wiki
- No additional updates can be captured at this time



REMINDER: USE FEDEX LABELS AND SPECIMEN LABELS PROVIDED IN THE KIT

MyeloMATCH Specimen Submission Form *(for paper-based submissions)*

Institution Instructions: Complete and submit this form for/with **all specimens** unless the Rave-based STMF is available. All specimens for a patient shipped to the same laboratory must be specified on this form. Send original in shipment. Keep a copy for your files. Fax completed form to the receiving laboratory; do not fax if using the Rave STMF.

Screening Participant ID: **Treatment Protocol Number:** **Treatment Participant ID:**

Patient Initials: *Last* *First* **Date of Birth:** **Biological Sex:** ○ Female ○ Male ○ Intersex

Protocol Collection Event *(i.e., Timepoint)*:

Date Shipped: **FEDEX Tracking Number:** **Bone Marrow Laterality:** ○ Left ○ Right ○ Bilateral

Shipped From (Site Name): **NCI CTEP Site ID:**

Shipped To *(specify 1 shipping recipient below)*:

- ○ Children's Hospital Los Angeles - Clinical Immunology Laboratory
- ○ Fred Hutchinson Cancer Center - Specialty Labs, Clinical Cancer Genomics Laboratory
- ○ Fred Hutchinson Cancer Research Center - Molecular Oncology
- ○ Frederick National Laboratory for Cancer Research - Molecular Characterization Laboratory (MoCha CLIA)
- ○ Nationwide Children's Hospital - SWOG Biospecimen Bank, Leukemia Division

FORMS AND REPORTS: Include all forms and reports as directed per protocol (e.g., pathology, cytogenetics, flow cytometry, patient consult, etc.).

Specimen Type *(specify only 1 per row)*	Specimen Collection Method *(specify only 1 per row)*	Container Type *(specify only 1 per row)*	Collection Date *(mm/dd/yyyy)*	Collection Time *(24 hr, hh:mm)*	Quantity *(e.g., Volume)*	Specimen ID *(affix only 1 provided label per row)*	Anatomical Collection Site *(specify only 1 per row)*	Local Specimen ID *(if available)*
○ Bone marrow aspirate ○ Whole blood ○ Buccal cells	○ Bone marrow aspiration ○ Phlebotomy ○ Buccal swab	○ EDTA tube ○ Sodium heparin tube ○ Streck tube ○ Cryovial					○ C42.1 - Bone marrow ○ C42.0 - Blood ○ C06.0 - Cheek mucosa	
○ Bone marrow aspirate ○ Whole blood ○ Buccal cells	○ Bone marrow aspiration ○ Phlebotomy ○ Buccal swab	○ EDTA tube ○ Sodium heparin tube ○ Streck tube ○ Cryovial					○ C42.1 - Bone marrow ○ C42.0 - Blood ○ C06.0 - Cheek mucosa	
○ Bone marrow aspirate ○ Whole blood ○ Buccal cells	○ Bone marrow aspiration ○ Phlebotomy ○ Buccal swab	○ EDTA tube ○ Sodium heparin tube ○ Streck tube ○ Cryovial					○ C42.1 - Bone marrow ○ C42.0 - Blood ○ C06.0 - Cheek mucosa	
○ Bone marrow aspirate ○ Whole blood ○ Buccal cells	○ Bone marrow aspiration ○ Phlebotomy ○ Buccal swab	○ EDTA tube ○ Sodium heparin tube ○ Streck tube ○ Cryovial					○ C42.1 - Bone marrow ○ C42.0 - Blood ○ C06.0 - Cheek mucosa	

CRA Name: **CRA Phone:** **CRA Email:**

If additional specimens need to be submitted for the same Patient/Timepoint/Shipping recipient, use a 2nd paper form: 1) complete the 'Screening Participant ID', 'Patient Initials' and 'FEDEX Tracking Number', and 2) complete specimen table rows specific to the additional number of specimens being submitted.

Email specimen submission questions to the MyeloMATCH Help Desk: myelo-match-support@mail.nih.gov. Website: https://service.cancer.gov/MyeloMATCH
Additional copies of this form are available on the CTSU Website for the MyeloMATCH Master Screening Protocol: https://www.ctsu.org.

Form Version April xx, 2024

RAVE Forms Review

Rave STMF/CLIA/PATHGRP Forms – Stakeholder Review

- Stakeholder Review is being initiated for the three specimen-related PMI Rave forms:

Rave Specimen Tracking Manifest Form (STMF)	Rave CLIA Laboratory Specimen Submission Form (CLIA)	Rave Pathology Group Form (PATHGRP)

- A review listing for each form will be sent to PMI Committee Stakeholders on 4/17/2024
- Review listing details must be reviewed/ discussed within each Member's respective organization
- Stakeholders must provide a response for each item specified in the form review listings
- Completed review listings should be sent to the PMI Standards Mailbox (pmistandards@nih.gov); copy gingerriley@westat.com
- Review activities should be completed within 2 weeks, ***by COB Wednesday May 1st, 2024***
- Immediately advise the PMI team if you have any questions or require assistance with this review or the provided listings

Example Listing

PMI CDISC-harmonized Rave Specimen Tracking Manifest Form (STMF) Review Listing

#	Rave Field OID (CDE Short Name/Alt Name)	Rave Draft Field Name (CDE Long Name+PID+CDE#+Ver#)	Field Label/Column Header	Permissible Values/PV Meanings	Field Reqs/ Add'l Comments	LPO Review Response [Agree/ Disagree/ Undecided]	LPO Review Comments
	Form OID "PMI_CDISC_STMF"						
1	*NOTE_MANIFEST*	NOTE_MANIFEST	***Manifest details </br>***	*n/a*	*Rave eCRF Section Header*		
2	*SITENOTE_STMF*	Site Note Type PID14537300_V1_0	*** Note/Error ***	*n/a*	*Rave eCRF Section Header*	Agree Disagree Undecided	
3	BEMFSTID	Biospecimen Events Domain Manifest Identifier PID8177491_V1_0	**Manifest ID**	*<non-enum>*	Mandatory field - derived Values generated by CSMS.		
4	BEMANIST	Biospecimen Events Domain Manifest Status PID8177492_V1_0	**Manifest status**	****Draft** ****Ready to ship** ****Shipped** ****Received**	Mandatory field		
5	BETPT	Biospecimen Events Domain Biospecimen Event Planned Time Point PID13966067_V1_0	**Collection event name**	*<non-enum>*	Mandatory field		
6	SITE_CTEPID	Study Site Identifier PID6380048_V1_0	**NCI (CTEP) code**	*<non-enum>*	Mandatory field		
7	SITENM	Site Name PID8177493_V1_0	**Institution name**	*<non-enum>*	Mandatory field		
8	SITECNAM	Site Clinical Research Associate Name PID8177494_V1_0	**CRA name**	*<non-enum>*	Mandatory field		

Next Steps

- After Stakeholder review has been completed, additional activities will be managed by the PMI Project Team including:



Next Steps

Open Discussion

Communication

Contact the PMI Mailbox for any PMI related questions & comments

pmistandards@nih.gov

The project team will respond within 48 hours with a response or a follow up

PMI Wiki

https://wiki.nci.nih.gov/display/CDISC/Precision+Medicine+Initiative

All presentations, recordings, minutes, project documents and releases will be posted on this wiki

Action Items Tracking

Action Item	Owner	Status/Updates
Identify a date to present the **Stakeholder Feedback** findings to the PMI Committee	Chioma Ani	Planned date to present findings to PMI Committee- 5/15/2024
Add the information for **How to Suspend a Protocol** for interim analysis to the user guide	Leila Abraham	Due to MM Activation Priorities, this item will be updated to the RSS User guide by 5/15/2024

NATIONAL CANCER INSTITUTE

www.cancer.gov www.cancer.gov/espanol

Appendix

CTEP CDISC Policy Governance Review

Compliance for Use of ALS Versions

- Standard forms built in the LPO's Global Library within **60 days** of production ALS release to reflect additions/updates included in the ALS
  - Example: Release ALSv7.X on November 1, LPOs would be expected to incorporate the ALSv7.X into their Global Library by January 1
  - ALS versions for new study builds
    - LPOs will be required to use the most current version of the ALS available at the time of each study build

Target Timeline

Nov – Mid Dec 2022

Group Activities
- Develop Study-specific Rave CRFs

NCI Activities
- ComboMATCH UAT Matchbox Environment
- MyeloMATCH UAT Matchbox Environment
- MATCHBox & OPEN Integrations for UAT
- Prepare Beta Screening & Treatment ALS files

Mid Dec 2022

NCI Activities
- Release EC Templatev1
- Release Beta Screening Protocol ALS
- Release Beta Treatment Protocol ALS
- aMOI List Approval and MATCHBox Upload

Mid Dec to Jan 30, 2023

Group Activities
- UAT Testing

NCI Activities
- Iterative updates to test findings (show-stoppers)

Target Timeline

Jan 31, 2023

NCI Activities
- Release EC Template v1
- Release Prod Screening Protocol ALS
- Release Prod Treatment Protocol ALS
- Release Prod Central Study ALS
- Release NCI OPEN Integrations for Prod
- Release NCI Genexus Installation (MyeloMATCH)

Jan 31 to Feb 14, 2023

NCI + Group Activities
- Support Group Study Builds

Feb 14, 2023

NCI + Group Activities
- Launch BOTH Initiatives

Spring 2023

NCI Activities
- Release Additional ALS(s)

ComboMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	8/15/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	8/15/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Olaparib (AZD2281) (747856) (O) Selumetinib (AZD6244 hydrogen sulfate) (748727)
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Nilotinib (747599) (O) Paclitaxel (Taxol) (673089)
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Binimetinib (788187) (O) Fulvestrant (Faslodex) (719276)
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	8/29/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Ipatasertib (781451) (O) Paclitaxel (Taxol) (673089)

ComboMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Approval on Hold 9/14/2022	Rev 4 approved by CIRB on 10/24. CTEP currently reviewing stips.	(P) Binimetinib (788187) (O) OXALIplatin (Eloxatin) (266046) (O) 5-Fluorouracil (5-FU) (19893) (O)Leucovorin calcium (3590)
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Approval on Hold 8/26/2022	Rev 2 sent to CIRB . Reviewed on 10/6, study team responding to stips	(P) Palbociclib (PD-0332991) (772256) (O) Binimetinib (788187)

ComboMATCH Priority 3 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	In Review 4/4/2022	Rev 3 recv;d 10/19, currently with LR. Looks like it'll be another disapproval. Not yet sent to CIRB for initial review.	(P) Olaparib (AZD2281) (747856) (O) Alpelisib (BYL719) (801658)
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	In Review 9/29/2022	Protocol reviewed at PRC 10/20; CR is being put together	(P) Selumetinib (AZD6244 hydrogen sulfate) (748727) (O) DAY101 (TAK-580, MLN-2480) (800798)
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	In Review 2/22/2022	Waiting for revision 2 since 9/28; reminder was sent to EA 10/24	(P) AMG 510 (Sotorasib) (825510) (O) Panitumumab (742319)
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	In Review 11/22/2021	Rev 3 disapproval sent 10/15; waiting for Rev 4	(P) Neratinib (783782) (O) Palbociclib (PD-0332991) (772256)

MyeloMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	11/12/2021: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	9/2/2022: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	9/2/2022: Approval on Hold	CIRB Review Oct 6, responding to stips
6	MM1OA-EA02 (Concept)	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	8/29/2022: Approved, no protocol yet	Waiting for protocol

MyeloMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	1/21/2022: In Review	Reviewed by CIRB, responding to stips
5	MM1OA-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	10/17/2022: In Review	Scheduled for PRC 11/4
7	MM1MDS-EA03 (Concept	ERADICATE MDS with TP53 Study: Efficacy of taRgeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for TrEatment of Higher Risk myElodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	8/12/2022: Approval on hold, waiting for drug commitment	W+A6:G8aiting for Astex commitment, Genentech has provided commitment on 10/20

Review Schemas

EAY191-N4


Protocol N4
EAY191-N4
People with:
• RAS Pathway Mutant (KRAS, NRAS, HRAS, NF1, BRAF)
• AND Ovarian (including primary peritoneal and fallopian tube) OR Endometrial Cancer
• Excludes:
◦ Prior MEK inhibitors
◦ Prior PARP inhibitors with disease progression (Prior PARP inhibitors are allowed if there was no disease progression)
Cohort 1
EAY191-N4.C1
People with Ovarian (including primary peritoneal and fallopian tube) Cancer
N = 85
Cohort 2
EAY191-N4.C2
People with Endometrial Cancer
N = 80
R
Treatment Regimen 1
EAY191-N4.C1.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C1.R2
(Selumetinib)
Participants on Treatment Regimen 2 that progress are eligible to crossover to Treatment Regimen 1 in the same Cohort
Treatment Regimen 1
EAY191-N4.C2.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C2.R2
(Selumetinib)
KEY
R Randomization

EAY191-E4


Protocol E4
EAY191-E4
People with:
• Previous taxane therapy (metastatic setting)
• Excludes:
◦ Platinum-resistant epithelial serous ovarian cancer
◦ cKIT variants
◦ PDGFRA D842V variants
N = 40
Treatment Regimen 1
EAY191-E4.R1
(Nilotinib + Paclitaxel)

EAY191-N2- Draft



EAY191-S3


Protocol S3
EAY191-S3
People with:
• Advanced or metastatic non-breast solid tumors
• A mutation in AKT1/AKT2/AKT3
• Progressed on prior taxane therapy
Excludes:
• Mutations in KRAS, NRAS, HRAS or BRAF
• Prior AKT inhibitor
N = 33
Treatment Regimen 1
EAY191-S3.R1
(Paclitaxel + Ipatasertib)

MMIYA-CTG01 Draft